New Label Expansion in Generalized Myasthenia Gravis - Quiz - MDSpire

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.

  • By

  • Kathryn Wighton

  • May 11, 2026

  • 2 min

Share

Original Source(s)

New Label Expansion in Generalized Myasthenia Gravis

  • by Kathryn Wighton

  • May 11, 2026

Related Content

Aid in Dying Nears One Third of US

New laws in New York and Illinois will soon make medical aid in dying available to nearly one-third of Americans.

Misdiagnosis Common in Parkinsonian Disorders

Autopsy-confirmed findings linked diagnostic errors, co-pathology, and genetic variation to distinct pathologic patterns across more than 3,300 donors with Parkinsonian disorders.

Early Neurodevelopmental Outcomes in Pediatric Congenital Heart Disease

In a multicenter registry study, genetic diagnoses were associated with substantially lower cognitive, language, and motor scores; while birth weight, surgical timing, hospitalization burden, and caregiver education were also associated with outcomes.